Rezera announces positive Resolve-2 Phase 2 results for ruvonoflast plus semaglutide
Phase 2 efficacy and safety outcomes for ruvonoflast with semaglutide could affect expectations for the programme’s clinical prospects.
Oct 7 (Reuters) — Rezera Announces Positive Resolve-2 Phase 2 Clinical Trial Results Demonstrating Favorable Safety And Tolerability Profile For Ruvonoflast In Combination With Semaglutide Rezera: Resolve-2 Phase 2 Trial Shows Ruvonoflast Plus Semaglutide Achieved Greater Hscrp Reductions Versus Semaglutide Alone Rezera: Ruvonoflast Combination Well-tolerated; No New Safety Signals Observed In Resolve-2 Source text:... com;)